Earlier and continuous treatment with ocrelizumab can provide long-term benefits on measures of disease progression in patients with primary progressive multiple sclerosis.
Why this matters
Patients with multiple sclerosis currently have limited treatment options available to prevent long-term disability progression.
The ongoing open-label extension of the ORATORIO study provides long-term safety and efficacy data over 6.5-years of follow-up. Treatment with ocrelizumab continues to show greater benefits on measures of disease progression in comparison to placebo treatment.